Rapport Announces Proposed Public Offering of Common Stock
1. Rapport Therapeutics announces a $250 million public offering of common stock. 2. An additional $37.5 million may be offered if underwriters exercise their option. 3. The offering is subject to market conditions and federal regulations. 4. Rapport focuses on precision medicines for neurological and psychiatric disorders. 5. Their lead drug, RAP-219, targets severe psychiatric and neurologic conditions.